Status:
COMPLETED
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patient...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Men and women, 18-65 years old
- Experienced a Major Depressive Disorder with the current episode of minimally 8 weeks in duration.
- Treatment history of an inadequate response to at least one and no more than three antidepressants.
Exclusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT00095758
Start Date
September 1 2004
End Date
December 1 2006
Last Update
November 25 2013
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Beverly Hills, California, United States
2
Local Institution
Burbank, California, United States
3
Local Institution
National City, California, United States
4
Local Institution
Orange, California, United States